Kymera Therapeutics (KYMR) Competitors $35.28 +0.73 (+2.11%) Closing price 04:00 PM EasternExtended Trading$35.33 +0.05 (+0.13%) As of 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KYMR vs. LNTH, RVMD, BBIO, LEGN, TGTX, TLX, BPMC, SRPT, AXSM, and NUVLShould you be buying Kymera Therapeutics stock or one of its competitors? The main competitors of Kymera Therapeutics include Lantheus (LNTH), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), Legend Biotech (LEGN), TG Therapeutics (TGTX), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Blueprint Medicines (BPMC), Sarepta Therapeutics (SRPT), Axsome Therapeutics (AXSM), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry. Kymera Therapeutics vs. Lantheus Revolution Medicines BridgeBio Pharma Legend Biotech TG Therapeutics Telix Pharmaceuticals Limited American Depositary Shares Blueprint Medicines Sarepta Therapeutics Axsome Therapeutics Nuvalent Kymera Therapeutics (NASDAQ:KYMR) and Lantheus (NASDAQ:LNTH) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, community ranking, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends. Does the MarketBeat Community prefer KYMR or LNTH? Lantheus received 285 more outperform votes than Kymera Therapeutics when rated by MarketBeat users. Likewise, 66.02% of users gave Lantheus an outperform vote while only 54.29% of users gave Kymera Therapeutics an outperform vote. CompanyUnderperformOutperformKymera TherapeuticsOutperform Votes5754.29% Underperform Votes4845.71% LantheusOutperform Votes34266.02% Underperform Votes17633.98% Do insiders and institutionals hold more shares of KYMR or LNTH? 99.1% of Lantheus shares are owned by institutional investors. 15.8% of Kymera Therapeutics shares are owned by insiders. Comparatively, 1.5% of Lantheus shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is KYMR or LNTH more profitable? Lantheus has a net margin of 28.57% compared to Kymera Therapeutics' net margin of -191.26%. Lantheus' return on equity of 44.29% beat Kymera Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Kymera Therapeutics-191.26% -24.96% -20.27% Lantheus 28.57%44.29%23.52% Do analysts prefer KYMR or LNTH? Kymera Therapeutics presently has a consensus target price of $56.36, indicating a potential upside of 59.74%. Lantheus has a consensus target price of $129.43, indicating a potential upside of 19.03%. Given Kymera Therapeutics' higher possible upside, analysts clearly believe Kymera Therapeutics is more favorable than Lantheus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kymera Therapeutics 0 Sell rating(s) 3 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.87Lantheus 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better earnings & valuation, KYMR or LNTH? Lantheus has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKymera Therapeutics$47.07M48.67-$146.96M-$2.97-11.88Lantheus$1.53B4.85$326.66M$4.3724.88 Which has more risk and volatility, KYMR or LNTH? Kymera Therapeutics has a beta of 2.22, suggesting that its stock price is 122% more volatile than the S&P 500. Comparatively, Lantheus has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500. Does the media prefer KYMR or LNTH? In the previous week, Lantheus had 9 more articles in the media than Kymera Therapeutics. MarketBeat recorded 18 mentions for Lantheus and 9 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 1.44 beat Lantheus' score of 1.26 indicating that Kymera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 12 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryLantheus beats Kymera Therapeutics on 12 of the 19 factors compared between the two stocks. Get Kymera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KYMR vs. The Competition Export to ExcelMetricKymera TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.29B$2.97B$5.55B$8.04BDividend YieldN/A1.87%5.09%4.22%P/E Ratio-15.0830.5222.6818.83Price / Sales48.67494.70404.28106.72Price / CashN/A168.6838.1834.62Price / Book4.963.216.794.33Net Income-$146.96M-$72.35M$3.22B$247.97M7 Day Performance6.07%3.75%2.44%2.71%1 Month Performance33.84%7.34%3.79%3.37%1 Year Performance-2.81%-22.52%17.06%5.80% Kymera Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KYMRKymera Therapeutics2.0327 of 5 stars$35.28+2.1%$56.36+59.7%-4.7%$2.29B$47.07M-15.08170News CoveragePositive NewsLNTHLantheus3.9942 of 5 stars$100.62-0.7%$129.43+28.6%+57.2%$6.89B$1.53B16.74700Upcoming EarningsPositive NewsRVMDRevolution Medicines3.769 of 5 stars$36.56-0.5%$66.67+82.3%+4.7%$6.80B$742,000.00-10.18250Upcoming EarningsPositive NewsBBIOBridgeBio Pharma4.5814 of 5 stars$33.51-1.1%$53.00+58.2%+42.1%$6.37B$221.90M-11.76400Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageLEGNLegend Biotech2.5246 of 5 stars$32.24-1.7%$79.00+145.0%-22.8%$5.92B$627.24M-33.941,070Positive NewsTGTXTG Therapeutics3.3393 of 5 stars$36.97-3.5%$40.67+10.0%+185.7%$5.81B$329.00M-369.66290Upcoming EarningsPositive NewsTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$16.21-3.0%$22.00+35.7%N/A$5.48B$783.21M0.00N/AAnalyst RevisionNews CoverageGap DownBPMCBlueprint Medicines1.7426 of 5 stars$84.18-0.6%$124.95+48.4%+4.6%$5.38B$508.82M-77.94640Earnings ReportAnalyst ForecastNews CoveragePositive NewsSRPTSarepta Therapeutics4.7694 of 5 stars$55.23+2.7%$158.70+187.3%-52.0%$5.36B$1.90B44.18840Upcoming EarningsAXSMAxsome Therapeutics4.8491 of 5 stars$103.00-1.4%$169.80+64.9%+49.9%$5.02B$385.69M-17.20380Upcoming EarningsAnalyst ForecastShort Interest ↓News CoveragePositive NewsNUVLNuvalent1.7164 of 5 stars$69.95-2.4%$115.50+65.1%+7.9%$5.01BN/A-20.1640Upcoming Earnings Related Companies and Tools Related Companies LNTH Competitors RVMD Competitors BBIO Competitors LEGN Competitors TGTX Competitors TLX Competitors BPMC Competitors SRPT Competitors AXSM Competitors NUVL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KYMR) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredElon Musk is all in on these robots …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kymera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kymera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KYMR Stock Free KYMR Stock Alerts